| INTERESTING CASE REPORT |
|
| Year : 2023 | Volume
: 7
| Issue : 1 | Page : 31-36 |
|
|
Effectiveness and Safety of Sacubitril/Valsartan for Heart Failure with Reduced Ejection Fraction Secondary to Duchenne Muscular Dystrophy-Associated Cardiomyopathy
Pankaj Jariwala, Kartik Jadhav, Saket Khetan
Department of Cardiology, Yashoda Hospitals, Hyderabad, Telangana, India
Correspondence Address:
Dr. Pankaj Jariwala
Department of Cardiology, Yashoda Hospitals, Somajiguda, Raj Bhavan Road, Hyderabad - 500 082, Telangana
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/jiae.jiae_17_22
|
|
|
In individuals with an ejection fraction of 40% or less, the use of sacubitril/valsartan significantly lowers mortality or hospitalization. There has been no research related to the effectiveness and safety of sacubitril/valsartan in patients with Duchenne muscular dystrophy (DMD)-associated cardiomyopathy. We hereby report a case of DMD-associated cardiomyopathy and heart failure with reduced ejection fraction who had been on routine guideline-directed medical treatment with no change in clinical or echocardiographic markers. When guideline-directed medical therapy was unsuccessful, sacubitril/valsartan was started which resulted in a significant change in functional class and significant ventricular remodeling, including an improvement in left ventricular (LV) ejection fraction, reduction in LV diastolic diameter, and a reduction in mitral regurgitation.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
